Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Vasculitis
•
Lupus nephritis
•
Cyclophosphamide
•
Scleroderma
•
SLE
When do you consider Mesna for patients taking oral cyclophosphamide?
What dose do you use? Do you utilize oral or IV infusion Mesna?
Related Questions
How would you approach a patient with newly diagnosed lupus/lupus nephritis receiving cyclophosphamide (euro lupus protocol) with active hemolysis not responding to steroids or IVIG?
What treatment regimen would you recommend for a patient with biopsy-proven giant cell arteritis and diffuse cutaneous systemic sclerosis?
Should patients starting cyclophosphamide be screened routinely for latent tuberculosis (TB)?
How do you approach management of a patient presenting with clinical manifestations of systemic sclerosis (cutaneous involvement, Raynaud’s phenomenon, and pulmonary arterial hypertension) but negative serologies?
What factors do you weigh most heavily when choosing between belimumab and voclosporin as part of a triple therapy regimen for newly diagnosed class IV LN?
Are there instances when you consider rituximab first line in a patient with class V LN?
How do you approach tapering of tocilizumab used for a history of GCA with vision loss?
Over what timeline do you typically try to escalate your LN patients to triple therapy?
How would you manage a patient with Takayasu arteritis controlled on TNFi who develops erythema nodosum that is only partially responsive to NSAIDs?
How would you approach management of a patient with mixed cryoglobulinemic vasculitis with predominant skin involvement and no major organ involvement?
